Vetter Development Service specializes in supporting the clinical development of products to market launch. Tailoring of the application system to the active substance can accelerate time-to-market and maximizes market impact. As experts in the handling of highly sensitive active substances, you can rely upon our experience in quick, efficient and careful production processes with freeze-dried active substances.
Prior to clinical production, pharmaceutical analyses are conducted to assess production feasibility. We then support the selection of the most suitable injection system to its specifications. Once the clinical stage is complete, we focus on finding methods for a gentle, swift and economic production of your product. At the same time we support your efforts to obtain the international regulatory approvals.
Consulting the Vetter experts at the earliest possible stage of the drug development saves time and money and will help your product to attain a decisive edge in the market.
Vetter Development Service includes:
Contact:
| Brigitte Reutter-Härle | Head of Corporate Marketing |
Vetter Commercial Manufacturing handles all aspects of drug production from sterile filling to custom-packing of the final product. We successfully apply a full range of cutting-edge technology in the sterile production of your product, such as Restricted Access Barrier Systems (RABS). Liquid parenteral drugs and lyophilized drugs are manufactured in our state-of-the-art manufacturing sites.
You can also rely upon our experience in the production (form, fill and finish) of modern biopharmaceutical drugs and our support through regulatory approval process. Our quality assurance system monitors the products and processes to ensure conformity with the agreed quality specifications and regulatory requirements.
Vetter Commercial Manufacturing includes:
Dosage forms: Syringes, cartridges, vials
Contact:
| Brigitte Reutter-Härle | Head of Corporate Marketing |
Vetter Solutions: As a result of our high quality, efficient production processes and patient-friendly designs, Vetter pre-filled systems excel in the marketplace. This is particularly true of our own patented innovations. Here are just a few examples.
The Vetter Lyo-Ject® dual-chamber ready-to-use syringe for example is designed for sensitive drugs which will not degrade in a lyophilized state. The actual active ingredient is lyophilized in one chamber, while the other chamber of the syringe contains a solvent that is mixed with the active substance immediately before application. This all-in-one concept provides for a long shelflife as well as easy handling. This also means higher yields of your active product ingredient and precision in dosing.
Our innovative systems not only appeal to patients, but also will help your product to attain a decisive edge in the marketplace. This creates genuine value added for our partners, our customers.
Vetter Solutions include:
· Dual-chamber technology, e. g. suitable for lyophilized, liquid and powdered substances:
- lyophilisate/solvent
- liquid/liquid
- powder/liquid
· Anti-Counterfeiting Solutions
Contact:
| Brigitte Reutter-Härle | Head of Corporate Marketing |
| Brigitte Reutter-Härle | Head of Corporate Marketing |
FDA gives Vetter the green light (27 Feb 2008)
Vetter Pharma-Fertigung GmbH & Co. has been granted approval by the Food and Drug Administration for the production of a new client drug.
Vetter is an independent international specialist in the production of aseptically pre-filled injection systems, cartridges and vials. For more than 25 years Vetter has been renowned for its quality, innovation and strategic partnerships.
The fact that our products and processes have been approved by the FDA, the EMEA and other authorities ensures the highest level of quality and safety. Vetter provides support for its pharmaceutical and biotech clients from the initial phases of development and regulatory approval process through to the successful product launch and market supply worldwide. Our innovative patented application systems will help your product to attain a decisive edge in the market.
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
